Home

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Daniel Carlson -
0
SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention...
Read more

The Rare 10 Bagger Initiation

Daniel Carlson -
4
The only thing more rare than a 10-bagger in the stock market? A Street analyst suggesting that a stock will be a 10-bagger. Yet,...
Read more

Trading Update for Premium Subscribers 10-3-24

Daniel Carlson -
2
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Daniel Carlson -
0
TW's Take: the safety profile of Anixa's treatment is obviously excellent if they are seeking approval for a second dose. Potential blockbuster treatment that...
Read more

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer’s Disease

Daniel Carlson -
0
Boca Raton, Florida, Sept. 30, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and...
Read more

Darkest Before The Dawn? It’s Pitch Black Right Now

Daniel Carlson -
3
They say that a definition of a gold mine is a piece of land with a liar standing on it. This generally plays out in...
Read more

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

Daniel Carlson -
3
TW's Take: not sure why the company needed to pad the balance sheet, but this is a nice endorsement from some smart shareholders. IRVINE, CA...
Read more

TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

Daniel Carlson -
0
TW's Take: more proof that thin-film-freezing is highly effective as a drug delivery methodology. Monetizing the technology is simply taking too long.  Newly published...
Read more

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Daniel Carlson -
0
TW's Take: excellent safety and initial efficacy. Later cohorts will determine just how efficacious this product will become. BOCA RATON, Fla., Sept. 26, 2024 (GLOBE...
Read more

Aeluma Provides Fourth Quarter and Fiscal Year 2024 Results

Daniel Carlson -
0
TW's Take: expect ALMU to be cash flow positive sometime next year which makes it a great value play on potentially massive upside opportunities. ...
Read more

Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine

Daniel Carlson -
0
TW's Take: This is a potentially big deal as results from this trial will start getting released to the market sometime in 2025. The...
Read more

FED Cuts Rates…Micro-Caps Should Benefit (Eventually)

Daniel Carlson -
3
This past week, the FED cut interest rates by 50 bps. This was likely the least unexpected rate cut in history, yet stocks took...
Read more

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer...

Daniel Carlson -
0
TW's Take: this novel therapy is gaining increasing recognition from the scientific community. SAN JOSE, Calif., Sept. 18, 2024 -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:...
Read more

Trading Update for Premium Subscribers

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer’s Disease...

Daniel Carlson -
0
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today...
Read more

Aeluma Achieves ISO 9001:2015 Certification for Quality Management System

Daniel Carlson -
0
TW's Take: interesting news as we await a large order from the automotive or mobile industries. Certification Underscores Commitment to Providing the Highest Quality Products...
Read more

There’s a Bull Market Somewhere

Daniel Carlson -
0
There are times when I have high conviction on the market. This is not one of those times. Twice in the past month and a...
Read more

INmune Bio Announces $13.0 Million Registered Direct Offering

Daniel Carlson -
0
TW's Take: puts roughly two additional Q's of cash on the balance sheet post expected data early next year. Boca Raton, Florida, Sept. 13, 2024...
Read more

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled...

Daniel Carlson -
3
TW's Take: BARDA is a great endorsement for the technology. TFFP's balance sheet issues notwithstanding, the value here for the tech is insane. Partnership funded...
Read more

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by...

Daniel Carlson -
0
TW's Take: more proof of the power of the TFF platform. If only funding were in place, the value here is crazy cheap. TFF-dry powder...
Read more

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.